Neumora Therapeutics, Inc. (NMRA) Form 10-K Annual Reports
Neumora Therapeutics, Inc. (NMRA) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: NMRA
CIK: 1885522
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Ernst & Young LLP
Auditor SinceSince 12/31/2022 12:00:00 AM
Lead Engagement PartnerKristen Pisani
Audit LocationSan Jose, California, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 4 | 2026-08-21 | 2026-08-20 | FORM 4 | 0001610717-26-000385 | View SEC Doc Filr Page |
| 4 | 2026-08-21 | 2026-08-20 | FORM 4 | 0001610717-26-000384 | View SEC Doc Filr Page |
| 4 | 2026-08-21 | 2026-08-20 | FORM 4 | 0001610717-26-000383 | View SEC Doc Filr Page |
| 4 | 2026-08-21 | 2026-08-20 | FORM 4 | 0001610717-26-000382 | View SEC Doc Filr Page |
| 4 | 2026-08-21 | 2026-08-20 | FORM 4 | 0001610717-26-000381 | View SEC Doc Filr Page |
| 144 | 2026-08-21 | — | 144 Filing | 0001964306-26-000408 | View SEC Doc Filr Page |
| 144 | 2026-08-20 | — | 144 Filing | 0001964306-26-000403 | View SEC Doc Filr Page |
| 4 | 2026-08-19 | 2026-08-17 | FORM 4 | 0001610717-26-000362 | View SEC Doc Filr Page |
| 144 | 2026-08-19 | — | 144 Filing | 0001964306-26-000401 | View SEC Doc Filr Page |
| 144 | 2026-08-18 | — | 144 Filing | 0001964306-26-000400 | View SEC Doc Filr Page |
| 144 | 2026-08-17 | — | 144 Filing | 0001964306-26-000398 | View SEC Doc Filr Page |
| 10-Q | 2026-08-14 | 2026-06-30 | 10-Q | 0001193125-26-350370 | View SEC Doc Filr Page |
| 8-K | 2026-08-14 | 2026-08-14 | 8-K | 0001193125-26-350349 | View SEC Doc Filr Page |
| 8-K | 2026-07-27 | 2026-07-27 | 8-K | 0001193125-26-316819 | View SEC Doc Filr Page |
| 8-K | 2026-06-15 | 2026-06-10 | 8-K | 0001193125-26-270328 | View SEC Doc Filr Page |
| 4 | 2026-05-29 | 2026-05-27 | 4 Filing | 0001610717-26-000174 | View SEC Doc Filr Page |
| 4 | 2026-05-29 | 2026-05-27 | 4 Filing | 0001610717-26-000173 | View SEC Doc Filr Page |
| 4 | 2026-05-29 | 2026-05-27 | 4 Filing | 0001610717-26-000171 | View SEC Doc Filr Page |
| 4 | 2026-05-29 | 2026-05-27 | 4 Filing | 0001610717-26-000170 | View SEC Doc Filr Page |
| 4 | 2026-05-29 | 2026-05-27 | 4 Filing | 0001610717-26-000169 | View SEC Doc Filr Page |
| 8-K | 2026-05-29 | 2026-05-27 | 8-K | 0001193125-26-248244 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-05-15 | — | SCHEDULE 13G/A Filing | 0000905148-26-002417 | View SEC Doc Filr Page |
| 10-Q | 2026-05-07 | 2026-03-31 | 10-Q | 0001193125-26-211825 | View SEC Doc Filr Page |
| 8-K | 2026-05-07 | 2026-05-07 | 8-K | 0001193125-26-210310 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-05-04 | — | SCHEDULE 13G/A Filing | 0002005369-26-000023 | View SEC Doc Filr Page |